Sickle Cell Disease Treatment Market

Sickle Cell Disease Treatment Market by Treatment Type (Pharmacotherapy, Bone Marrow Transplant, and Blood Transfusion), by End User (Hospitals, and Specialty Clinics), - Global Outlook & Forecast 2022-2030

GR - 339664 Category: Pharmaceuticals

Number of pages: 100 | Report Format: PDF | Published date: September 08, 2022

Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030

Sickle Cell Disease Treatment Market Scope

Report Attribute	Details
Market size value in 2021	USD 2.3 Billion
Revenue forecast in 2030	USD 8.28 Billion
Growth Rate	CAGR of 15.3% from 2022 to 2030
Base year for estimation	2021
Forecast period	2022-2030
Segments covered	Treatment Type, End User, and Region
Regional scope	North America, Europe, Asia Pacific, and the Rest of the World (ROW)

Report Overview

The global sickle cell disease treatment market was pegged at US$ 2.3 billion in 2021 and is expected to register a revenue CAGR of 15.3% during the forecast period.

Market Fundamentals

Red blood cells (RBCs) with aberrant, rigid sickle shapes are the hallmark of sickle cell disease (SCD), a genetic blood illness brought on by mutations in the beta-globin gene. From person to person, the disease's severity varies greatly. This illness is characterized by a low level of red blood cells (anemia), recurrent infections, and cyclical pain episodes. The rising prevalence of sickle cell illness is the major factor fueling the revenue growth of the sickle cell treatment market.

[3434334]

Market Dynamic

The rising prevalence of sickle cell illness is the main factor fueling the revenue growth of the sickle cell treatment market. Additionally, rising R&D activities, a strong pipeline, and a growing patient base are all expected to have a positive impact on the market revenue growth. The global sickle cell disease treatment market revenue growth is expected to be driven by several factors, including an increase in immigration, better healthcare services, and a large population of people of African heritage. To some extent, the market's revenue expansion is also influenced by the approval of new products.

The revenue growth of the market is constrained by the high cost of the treatment. Patients stop taking their medication in the middle of dosage because of the expensive lifelong treatment and a lack of reimbursement.

Market Ecosystem

The global sickle cell disease treatment market is analyzed from three perspectives: treatment type, end-user, and region.

Sickle Cell Disease Treatment Market by Treatment Type

[52342343]

Based on treatment type, the global sickle cell disease treatment market is segmented into, pharmacotherapy, bone marrow transplant, and blood transfusion.

The blood transfusion segment is expected to register stable revenue growth during the forecast period. The increased demand for blood transfusions in sickle cell therapy and the rise in SCD prevalence are expected to drive the revenue growth of the segment. The ability to get normal red blood cells through blood transfusions increases hemoglobin levels to improve oxygen delivery in the body, lowering sickle cell anemia and the drive to produce more sickle cells.

The bone marrow transplant (BMT) segment is expected to register significant revenue growth because it is the only treatment for sickle cell disease, hence the preference for this therapy option is increasing to some extent, lately.

Sickle Cell Disease Treatment Market by End User

Based on the end user, the global sickle cell disease treatment market is segmented into hospitals and specialty clinics.

Vaso occlusive crisis is the primary factor driving sickle cell disease patients to hospitals, hence the hospital segment dominates the sickle cell disease treatment market in terms of revenue share.

Sickle Cell Disease Treatment Market by Region

Based on region, the global sickle cell disease treatment market is segmented into North America, Europe, Asia Pacific, and the Rest of the World.

North America dominates the overall sickle cell disease treatment market, with the United States being the major contributor to the market revenue. The revenue growth in the region is attributed to improving access to sickle cell disease treatment and potential pipeline candidates. Additionally, increasing births with sickle cell disease in the US is also increasing the demand for sickle cell treatment in this region.

Competitive Landscape

The prominent players operating in the global sickle cell disease treatment market are:

AstraZeneca Plc.
Pfizer Inc.
Bristol-Myers Squibb Company
Emmaus Life Sciences, Inc.
Arena Pharmaceuticals, Inc.
Bluebird Bio
Global Blood Therapeutics Inc.
Sangamo Therapeutics, Inc.
Eli Lilly and Company
Alnylam Pharmaceuticals, Inc.

Strategic Developments

In September 2022, Novo Nordisk acquired Forma Therapeutics, giving it access to the sickle cell disease portfolio and rare blood medicine.
In August 2022, Pfizer Inc. acquired Global Blood Therapeutics (GBT), a biopharmaceutical company specializing in sickle cell disease (SCD) treatment, to strengthen its sickle cell disease portfolio.

Frequently Asked Questions About This Report

The global sickle cell disease treatment market is expected to register at a revenue CAGR of 15.3% during the forecast period.

Increased research in the field of rare diseases is one of the key factors governing the revenue growth of the global sickle cell disease treatment market.

Eli Lilly, AstraZeneca, and Pfizer are among the key players operating in the global sickle cell disease treatment market.

The blood transfusion segment dominates the global sickle cell disease treatment in terms of market revenue.

Asia Pacific region is expected to register the highest revenue CAGR during the forecast period.

INTRODUCTION
1. Market Ecosystem
2. Timeline Under Consideration
  1. Historical Years – 2020
  2. Base Year – 2021
  3. Forecasted Years – 2022 to 2030
Currency Used in the Report
RESEARCH METHODOLOGY
1. Research Approach
2. Data Collection Methodology
3. Data Sources
  1. Secondary Sources
  2. Primary Sources
4. Market Estimation Approach
  1. Bottom Up
  2. Top Down
5. Market Forecasting Model
6. Limitations and Assumptions
PREMIUM INSIGHTS
1. Current Market Trends (COVID-19 Perspective)
2. Key Players & Competitive Positioning (2021)
MARKET DYNAMICS
1. Drivers
2. Restraints/Challenges
3. Opportunities
GLOBAL SICKLE CELL DISEASE TREATMENT MARKET - ANALYSIS & FORECAST, BY TREATMENT TYPE
1. Pharmacotherapy
2. Bone Marrow Transplant
3. Blood Transfusion
GLOBAL SICKLE CELL DISEASE TREATMENT MARKET - ANALYSIS & FORECAST, BY END USER
1. Hospitals
2. Specialty Clinics
3. Others
GLOBAL SICKLE CELL DISEASE TREATMENT MARKET - ANALYSIS & FORECAST, BY REGION
1. North America Sickle Cell Disease Treatment Market
  1. North America Sickle Cell Disease Treatment Market, by Treatment Type
  2. North America Sickle Cell Disease Treatment Market, by End User
  3. North America Sickle Cell Disease Treatment Market, by Country
    1. U.S.
      1. U.S. Sickle Cell Disease Treatment Market, by Treatment Type
      2. U.S. Sickle Cell Disease Treatment Market, by End User
    2. Canada
      1. Canada Sickle Cell Disease Treatment Market, by Treatment Type
      2. Canada Sickle Cell Disease Treatment Market, by End User
2. Europe Sickle Cell Disease Treatment Market
  1. Europe Sickle Cell Disease Treatment Market, by Treatment Type
  2. Europe Sickle Cell Disease Treatment Market, by End User
  3. Europe Sickle Cell Disease Treatment Market, by Country/Region
    1. Germany
      1. Germany Sickle Cell Disease Treatment Market, by Treatment Type
      2. Germany Sickle Cell Disease Treatment Market, by End User
    2. U.K.
      1. U.K. Sickle Cell Disease Treatment Market, by Treatment Type
      2. U.K. Sickle Cell Disease Treatment Market, by End User
    3. Spain
      1. Spain Sickle Cell Disease Treatment Market, by Treatment Type
      2. Spain Sickle Cell Disease Treatment Market, by End User
    4. Italy
      1. Italy Sickle Cell Disease Treatment Market, by Treatment Type
      2. Italy Sickle Cell Disease Treatment Market, by End User
    5. France
      1. France Sickle Cell Disease Treatment Market, by Treatment Type
      2. France Sickle Cell Disease Treatment Market, by End User
    6. Rest of Europe
      1. Rest of Europe Sickle Cell Disease Treatment Market, by Treatment Type
      2. Rest of Europe Sickle Cell Disease Treatment Market, by End User
3. Asia Pacific Sickle Cell Disease Treatment Market
  1. Asia Pacific Sickle Cell Disease Treatment Market, by Treatment Type
  2. Asia Pacific Sickle Cell Disease Treatment Market, by End User
  3. Asia Pacific Sickle Cell Disease Treatment Market, by Country/Region
    1. China
      1. China Sickle Cell Disease Treatment Market, by Treatment Type
      2. China Sickle Cell Disease Treatment Market, by End User
    2. Japan
      1. Japan Sickle Cell Disease Treatment Market, by Treatment Type
      2. Japan Sickle Cell Disease Treatment Market, by End User
    3. India
      1. India Sickle Cell Disease Treatment Market, by Treatment Type
      2. India Sickle Cell Disease Treatment Market, by End User
    4. South Korea
      1. South Korea Sickle Cell Disease Treatment Market, by Treatment Type
      2. South Korea Sickle Cell Disease Treatment Market, by End User
    5. Australia
      1. Australia Sickle Cell Disease Treatment Market, by Treatment Type
      2. Australia Sickle Cell Disease Treatment Market, by End User
    6. Rest of Asia Pacific
      1. Rest of Asia Pacific Sickle Cell Disease Treatment Market, by Treatment Type
      2. Rest of Asia Pacific Sickle Cell Disease Treatment Market, by End User
4. Rest of the World Sickle Cell Disease Treatment Market
  1. Rest of the World Sickle Cell Disease Treatment Market, by Treatment Type
  2. Rest of the World Sickle Cell Disease Treatment Market, by End User
  3. Rest of the World Sickle Cell Disease Treatment Market, By Region
    1. Latin America
      1. Latin America Sickle Cell Disease Treatment Market, by Treatment Type
      2. Latin America Sickle Cell Disease Treatment Market, by End User
    2. Middle East & Africa
      1. Middle East & Africa Sickle Cell Disease Treatment Market, by Treatment Type
      2. Middle East & Africa Sickle Cell Disease Treatment Market, by End User
COMPANY PROFILES
1. AstraZeneca Plc.
  1. Business Snapshot
  2. Ingredient Type s/Services Offered
  3. Financial Details*
  4. Strategic Developments
2. Pfizer Inc.
3. Bristol-Myers Squibb Company
4. Emmaus Life Sciences, Inc.
5. Arena Pharmaceuticals, Inc.
6. Bluebird Bio
7. Global Blood Therapeutics Inc.
8. Sangamo Therapeutics, Inc.
9. Eli Lilly and Company
10. Alnylam Pharmaceuticals, Inc.

*Insights on financial permanence is subject to availability of information in public domain

Single User License

Multi User License

Enterprise User License

$4,750.00

What are the significant driving and restraining factors for the Sickle Cell Disease Treatment Market?
Who are the leading companies in the market?
Where can you find the updates on recent developments by market players?
When is the right time to get discounts on complete market reports?
Why to invest in the Sickle Cell Disease Treatment Market?
How to improve your organizational performance?
How to shift customers towards your brand?

Ask For Customization Check Discount Inquire Before Buying

Recommended Reports